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Fifty years ago, on 3 December 1967, the world’s first human-to-
human heart transplant was performed by Dr Christiaan Barnard 
at Groote Schuur Hospital in Cape Town. This was, and probably 
will remain, the most publicised medical event of all time, making 
headlines in nearly every international newspaper, magazine and 
tabloid within days of the event. The idea of transplanting a heart 
from one human to another captured the minds and imaginations of 
the public like no other medical event before or since. The only other 
iconic event in that era that was equally well publicised was man’s first 
landing on the moon 18 months later.
This medical breakthrough was published in the SAMJ 3 weeks 
later, towards the end of December 1967, and is one of the most cited 
articles in this journal.
The first heart transplant placed Groote Schuur Hospital, the 
University of Cape Town and South Africa (SA) firmly on the 
international medical map. A heart transplant was seen by the 
public as transplanting the very soul of an individual from one 
person into another. It provoked tremendous debate, some of it 
very emotional, around the ethics of transplantation and spurred 
on the international medical and philosophy community to develop 
the concept of brain death into law. Many countries took decades to 
adopt such laws – most notably Japan, which took another 30 years 
(until 1997) to allow organ transplantation from brain-dead donors. 
Even today many countries do not accept brain death, preventing 
organ transplantation as a therapeutic option for end-stage heart 
failure.
This tremendous publicity generated by the first heart 
transplant occurred despite kidney and liver transplantation 
having preceded heart transplantation by many years. These prior 
surgical innovations were instrumental in paving the way for 
immunosuppression, vital for modifying the recipient immune 
response and preventing rejection from a genetically non-identical 
donor. The suppression of host rejection as well as the prevention 
and treatment of subsequent side-effects remains the biggest 
challenge in organ transplantation.
Ultimately, the goal of a transplant is to improve both length and 
quality of life when medication and conventional cardiac surgery will 
not adequately alleviate symptoms of heart failure. As far as possible, 
transplant teams strive to help the recipient lead a life similar in quality 
to that of his or her peers, unconstrained by the limitations of heart 
failure.
The operation itself as performed today has changed very little 
since Dr Norman Shumway of Stanford University in the USA first 
described the technique in animals in the early 1960s. Small technical 
variations, the use of heart-preservation solutions (cardioplegia), 
and improvements in the heart-lung machine have optimised this 
procedure through the decades. The lack of donors has also been 
offset by the use of implantable mechanical assist devices (miniature 
pumps that help the heart), and even a totally artificial heart, as a 
bridge to transplantation, as well as the recent use of donors whose 
hearts have stopped (donation after circulatory death: DCD), which 
would previously have been deemed unsuitable for transplantation. 
The expensive equipment required to resuscitate these DCD hearts 
is not available in SA at present, however, and mechanical assist 
devices are currently only accessible to patients with excellent 
health insurance. In those developed countries that can afford their 
extended use, mechanical assist devices are increasingly being used as 
permanent treatment for heart failure, so-called destination therapy, 
because of the dearth of donor organs.
Progress in postoperative critical care has significantly improved 
early outcomes of heart transplantation, and patients without 
complications are discharged from the intensive care unit in 4 days 
or less. In the past year Groote Schuur Hospital has instituted a long-
term extracorporeal membrane oxygenation (ECMO) service, which 
brings the unit in line with international standards for postoperative 
care in complicated cases.
Approximately 15 years after the first heart transplant, in the 
early 1980s a ‘miracle’ drug called cyclosporine was discovered by 
Jean Borel, earning him a Nobel Prize. This drug was a significant 
breakthrough in the management of donor organ rejection, and 
transformed transplantation from an experimental operation in 
leading academic medical centres to standard medical treatment 
for end-stage organ failure with reproducible results that could be 
applied more widely. The numbers of all organ transplants rapidly 
escalated in the early 1980s, reaching a plateau a decade later 
when the availability of donor organs became the major constraint. 
Cyclosporine is a member of the class of drugs called calcineurin 
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The cover of the SAMJ of 30 December 1976, signed by some of the members 
of the heart transplant team. From the top in a clockwise direction, the 
signatures are those of Prof. Chris Barnard, Prof. Val Schrire (cardiologist 
and head of the cardiac clinic at Groote Schuur Hospital/University of Cape 
Town), Dr M C Botha (haematologist/immunologist), Dr Terry O’Donovan 
(surgeon), Dr S C Bosman (surgeon), Dr Joe (Oz) Ozinsky (anaesthetist), 
Dr Rodney Hewitson (senior surgeon), and Dr Coert Venter (junior surgeon in 
training). Two key articles from the issue are reprinted in this edition of SAMJ.
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inhibitors (Sandimmun and Neoral are the commercial formulations 
of the drug), and the other commonly used drug in this class is 
tacrolimus (Prograft or Advagraft).
Calcineurin inhibitors are still the mainstay of treatment in organ 
transplantation, and their use has led to significantly fewer rejection 
episodes and longer life expectancy. However, unwanted side-
effects are a concern with this more effective immunosuppression. 
Increased incidences of infection, hyper tension, nephrotoxicity and 
in some instances long-term renal failure, diabetes, high cholesterol 
and cancers are some of the side-effects of immunosuppression. 
The newer immunosuppressive drugs show promise of a reduction 
in some of these side-effects with or without some calcineurin 
inhibition, and provide physicians with a larger armamentarium to 
treat patients. The medical management of heart transplant recipients 
remains an ongoing challenge during the period immediately after 
the transplant, as well as in the long term.
Following the significant milestone 50 years ago, the Christiaan 
Barnard Division of Cardiothoracic Surgery at the University of 
Cape Town and Groote Schuur and Red Cross War Memorial 
Children’s hospitals has transplanted 537 hearts and remains the 
only heart transplant facility for both indigent and insured patients 
in SA. Despite the challenges that exist with heart transplantation, 
the outcome has improved significantly over the past 20 years. The 
functional status of the recipient after the procedure is generally 
excellent, depending on his or her motivation, with an expected 85% 
survival rate at 1 year, decreasing to 75% at 5 years.
The Christiaan Barnard Division of Cardiothoracic Surgery is the 
proud host of an international celebration to commemorate the 50th 
anniversary of the world’s first heart transplant, ‘50 years of Heart 
Transplantation: Courage and Innovation’, on 2 - 4 December 2017 at 
Groote Schuur Hospital.
We hope that the celebration of this courageous and innovative 
event will not only encourage further innovations in the management 
of heart failure, which constitutes a major burden of disease, but 
also inspire young academics to follow in the footsteps of Christiaan 
Barnard and his team five decades later.
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Some of the members of the team that performed the first heart transplant, photographed on 3 December 1967 (photo: First Heart Transplant Museum, 
Groote Schuur Hospital). The full team is listed on p. 1037 of this issue.
